Hemodynamic effects of the non-peptidic angiotensin-(1-7) agonist AVE0991 in liver cirrhosis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Klein, Sabine ^a   Herath, Chandana B ^b   Schierwagen, Robert ^a   Grace, Josephine ^b   Haltenhof, Tom ^c   Uschner, Frank E ^a   Strassburg, Christian P ^a   Sauerbruch, Tilman ^a   Walther, Thomas ^c,d   Angus, Peter W ^e   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; JANUS KINASE 2; MOESIN; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; RHO KINASE; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FLUOROMETRY; HEMODYNAMICS; IN VIVO STUDY; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SHORT COURSE THERAPY; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL LIVER CIRRHOSIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS, EXPERIMENTAL; PEPTIDYL-DIPEPTIDASE A; PORTAL PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE;

EID: 84947717104     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138732     Document Type: Article

References (35)

1. Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, et al. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 2013;145:874-84.e5. doi: 10.1053/j.gastro.2013.06.036 PMID: 23796456
2. Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014. doi: 10.1002/hep. 27117 PMID: 24619965
3. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008;57:1300-14. doi: 10.1136/gut.2007.144584 PMID: 18445644
4. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci 2012;123:225-39. doi: 10.1042/CS20120030 PMID: 22548407
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. doi: 10.1172/JCI24282 PMID: 15690074
6. Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, et al. Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003;33:1006-12. PMID: 14636305
7. Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int 2005;25:657-66. doi: 10.1111/j.1478-3231.2005.01053.x PMID: 15910503
8. Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 2009;296:G147-56. doi: 10.1152/ajpgi.00462.2007 PMID: 19056767
9. Lubel JS, Herath CB, Tchongue J, Grace J, Jia Z, Spencer K, et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clin Sci 2009;117:375-86. doi: 10.1042/CS20080647 PMID: 19371232
10. Silva DMR, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos R a. S, Lemos VS. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 2007;28:702-7. doi: 10.1016/j.peptides.2006.10.007 PMID: 17129638
11. Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension 2002;40:847-52. PMID: 12468568
12. Herath CB, Mak K, Burrell LM, Angus PW. Angiotensin-(1-7) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver. Am J Physiol Gastrointest Liver Physiol 2013;304:G99-108. doi: 10.1152/ajpgi.00163.2012 PMID: 23086915
13. Bosnyak S, Jones ES, Christopoulos A, Aguilar M-I, Thomas WG, Widdop RE. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci 2011;121:297-303. doi: 10. 1042/CS20110036 PMID: 21542804
14. Singh K, Sharma K, Singh M, Sharma PL. Possible mechanism of the cardio-renal protective effects of AVE-0991, a non-peptide Mas-receptor agonist, in diabetic rats. J Renin Angiotensin Aldosterone Syst 2012;13:334-40. doi: 10.1177/1470320311435534 PMID: 22345112
15. Santos RAS, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006;24:239-46. doi: 10.1111/j.1527-3466.2006.00239.x PMID: 17214600
16. Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, et al. Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury. Int J Hypertens 2012;2012:808726. doi: 10.1155/2012/808726 PMID: 22319645
17. Pinheiro SVB, Simões e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 2004;44:490-6. doi: 10.1161/01. HYP.0000141438.64887.42 PMID: 15326087
18. Suski M, Olszanecki R, Stachowicz A, Madej J, Bujak-Giżycka B, Okoń K, et al. The influence of angiotensin-(1-7) Mas receptor agonist (AVE 0991) on mitochondrial proteome in kidneys of apoE knockout mice. Biochim Biophys Acta 2013;1834:2463-9. doi: 10.1016/j.bbapap. 2013.08.008 PMID: 23988828
19. Rodrigues-Machado MG, Magalhães GS, Cardoso JA, Kangussu LM, Murari A, Caliari MV, et al. AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma. Br J Pharmacol 2013;170:835-46. doi: 10.1111/bph.12318 PMID: 23889691
20. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-53. doi: 10.1002/hep. 21673 PMID: 17596891
21. Trebicka J, Hennenberg M, Schulze Pröbsting A, Laleman W, Klein S, Granzow M, et al. Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 2009;50:1924-35. doi: 10.1002/hep. 23222 PMID: 19842096
22. Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012;57:1220-7. doi: 10.1016/j.jhep. 2012.07.033 PMID: 22878469
23. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2008;47:1264-76. doi: 10.1002/hep. 22170 PMID: 18318439
24. Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol 2009;297:G98-106. doi: 10.1152/ajpgi.00045.2009 PMID: 19389807
25. Maul B, Siems WE, Hoehe MR, Grecksch G, Bader M, Walther T. Alcohol consumption is controlled by angiotensin II. FASEB J 2001;15:1640-2. PMID: 11427512
26. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-43. doi: 10.1074/jbc. M200581200 PMID: 11815627
27. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010;53:702-12. doi: 10.1016/j.jhep. 2010.04.025 PMID: 20633948
28. James J, Bosch KS, Aronson DC, Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver 1990;10:1-5. PMID: 2308475
29. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999;117:669-77. PMID: 10464144
30. Sheng-Long C, Yan-Xin W, Yi-Yi H, Ming F, Jian-Gui H, Yi-Li C, et al. AVE0991, a Nonpeptide Compound, Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation via Induction of Heme Oxygenase-1 and Downregulation of p-38 MAPK Phosphorylation. Int J Hypertens 2012;2012. doi: 10.1155/2012/958298 PMID: 22518299
31. Lemos VS, Silva DMR, Walther T, Alenina N, Bader M, Santos RAS. The endothelium-dependent vasodilator effect of the nonpeptide Ang (1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 2005;46:274-9. PMID: 16116331
32. Ferreira AJ, Jacoby BA, Araújo CAA, Macedo FAFF, Silva GAB, Almeida AP, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 2007;292:H1113-9. doi: 10.1152/ajpheart.00828.2006 PMID: 17056670
33. Ferreira AJ, Santos RAS, Almeida AP. Angiotensin-(1-7): Cardioprotective Effect in Myocardial Ischemia/Reperfusion. Hypertension 2001;38:665-8. doi: 10.1161/01. HYP.38.3.665 PMID: 11566952
34. Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, et al. Upregulation of hepatic angiotensinconverting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007;47:387-95. doi: 10.1016/j.jhep. 2007.03.008 PMID: 17532087
35. Gao R, Li L, Xie C, Diao X, Zhong D, Chen X. Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9. Drug Metab Dispos 2012;40:556-67. doi: 10.1124/dmd.111.042689 PMID: 22184458